Optimizing Investments in Kazakhstan's HIV Response
As part of a Regional initiative, Kazakhstan conducted an Human Immunodeficiency Virus (HIV) allocative efficiency analysis in 2014 to 2015 to inform more strategic investment in HIV programs. Kazakhstan continues to experience a concentrated HIV...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Working Paper |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2016
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2016/07/26570531/optimizing-investments-kazakhstans-hiv-response http://hdl.handle.net/10986/24965 |
| id |
okr-10986-24965 |
|---|---|
| recordtype |
oai_dc |
| spelling |
okr-10986-249652021-06-14T10:17:46Z Optimizing Investments in Kazakhstan's HIV Response World Bank Benedikt, Clemens Wilson, David Masaki, Emiko Görgens, Marelize Obst, Michael health financing HIV antiretroviral therapy opioid substitution therapy health expenditure aid disbursements As part of a Regional initiative, Kazakhstan conducted an Human Immunodeficiency Virus (HIV) allocative efficiency analysis in 2014 to 2015 to inform more strategic investment in HIV programs. Kazakhstan continues to experience a concentrated HIV epidemic in which the majority of new infections occurred among key populations, particularly PWID, MSM, prison inmates, FSW, and their clients. Under current conditions (constant behaviors and program coverage), new HIV infections are projected to rise by 13 percent and deaths by 32 percent. The epidemics among PWID and MSM are projected to account for 67 percent of new HIV infections from 2015 to 2020 so need to be a core focus of programs. With optimized allocations, the cost to achieve national targets (no increase in incidence and deaths from 2015 to 2020) would be US 52 million dollars per year. The cost to achieve more ambitious future HIV response targets was estimated at US 80 million dollars.In conclusion, a combination of various efficiency gains in Kazakhstan’s HIV response can halve new HIV infections and deaths, achieving ambitious national targets at no additional cost. As a first priority, ART will be essential for reducing deaths and new infections, but unit costs need to be reviewed and reduced. A second consistent finding is the continued need to provide HIV services for PWID at scale. A third consistent finding is the need to scale up programs for MSM and at least double the current low coverage levels. Additional technical efficiency analysis is worth considering to explore the concrete pathways to achieve the proposed cost reductions for ART, OST, and management costs. 2016-08-29T16:46:08Z 2016-08-29T16:46:08Z 2016-03-01 Working Paper http://documents.worldbank.org/curated/en/2016/07/26570531/optimizing-investments-kazakhstans-hiv-response http://hdl.handle.net/10986/24965 English en_US CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo/ World Bank World Bank, Washington, DC Publications & Research Publications & Research :: Working Paper Europe and Central Asia Kazakhstan |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
health financing HIV antiretroviral therapy opioid substitution therapy health expenditure aid disbursements |
| spellingShingle |
health financing HIV antiretroviral therapy opioid substitution therapy health expenditure aid disbursements World Bank Optimizing Investments in Kazakhstan's HIV Response |
| geographic_facet |
Europe and Central Asia Kazakhstan |
| description |
As part of a Regional initiative,
Kazakhstan conducted an Human Immunodeficiency Virus (HIV)
allocative efficiency analysis in 2014 to 2015 to inform
more strategic investment in HIV programs. Kazakhstan
continues to experience a concentrated HIV epidemic in which
the majority of new infections occurred among key
populations, particularly PWID, MSM, prison inmates, FSW,
and their clients. Under current conditions (constant
behaviors and program coverage), new HIV infections are
projected to rise by 13 percent and deaths by 32 percent.
The epidemics among PWID and MSM are projected to account
for 67 percent of new HIV infections from 2015 to 2020 so
need to be a core focus of programs. With optimized
allocations, the cost to achieve national targets (no
increase in incidence and deaths from 2015 to 2020) would be
US 52 million dollars per year. The cost to achieve more
ambitious future HIV response targets was estimated at US 80
million dollars.In conclusion, a combination of various
efficiency gains in Kazakhstan’s HIV response can halve new
HIV infections and deaths, achieving ambitious national
targets at no additional cost. As a first priority, ART will
be essential for reducing deaths and new infections, but
unit costs need to be reviewed and reduced. A second
consistent finding is the continued need to provide HIV
services for PWID at scale. A third consistent finding is
the need to scale up programs for MSM and at least double
the current low coverage levels. Additional technical
efficiency analysis is worth considering to explore the
concrete pathways to achieve the proposed cost reductions
for ART, OST, and management costs. |
| author2 |
Benedikt, Clemens |
| author_facet |
Benedikt, Clemens World Bank |
| format |
Working Paper |
| author |
World Bank |
| author_sort |
World Bank |
| title |
Optimizing Investments in Kazakhstan's HIV Response |
| title_short |
Optimizing Investments in Kazakhstan's HIV Response |
| title_full |
Optimizing Investments in Kazakhstan's HIV Response |
| title_fullStr |
Optimizing Investments in Kazakhstan's HIV Response |
| title_full_unstemmed |
Optimizing Investments in Kazakhstan's HIV Response |
| title_sort |
optimizing investments in kazakhstan's hiv response |
| publisher |
World Bank, Washington, DC |
| publishDate |
2016 |
| url |
http://documents.worldbank.org/curated/en/2016/07/26570531/optimizing-investments-kazakhstans-hiv-response http://hdl.handle.net/10986/24965 |
| _version_ |
1764457972833976320 |